-
Optimizing Colorectal Cancer Screening in the Czech Republic: Cost-Effectiveness of Lowering the Starting Age to 45 and Introducing an Upper Limit
Sep 9, 2025, 16:22 PM -
Trends and Tensions in NICE Severity Modifiers: Analyzing the Acceptance and Critique of Manufacturer Severity Modifier Proposals in Recent Appraisals
Sep 9, 2025, 16:22 PM -
Budget Impact of Anakinra in Turkiye: An Analysis From the Social Security Institution’s Perspective
Sep 9, 2025, 16:22 PM -
Improving Kidney Exchange Program Effectiveness and Equity by Using Allele and Eplet HLA Compatibility Technologies
Sep 9, 2025, 16:22 PM -
The Cost-Effectiveness of Imlifidase Idefirix® for Desensitization Treatment of Highly Sensitized Adult Kidney Transplant Patients in Ireland
Sep 9, 2025, 16:22 PM -
Single-Arm Trials and Reimbursement Decision Making in Europe: A Case Study in Non-Small Cell Lung Cancer
Sep 9, 2025, 16:22 PM -
Cost Comparison of Symptom Treatment in Atopic Dermatitis Using Upadacitinib and Dupilumab in Poland
Sep 9, 2025, 16:22 PM -
From the Outside Looking in: Patient Advocacy Groups' and Healthcare Providers' Perspectives on Patient Engagement Strategies in the Israeli Health Technology Assessment Process
Sep 9, 2025, 16:22 PM -
Is Protocolized Stopping Lifelong Therapy With Eculizumab With Disease Monitoring and Retreatment for Eligible Atypical Hemolytic Uremic Syndrome (aHUS) Patients Cost-Effective? An Economic Evaluation of the SETS aHUS Trial
Sep 9, 2025, 16:22 PM -
Systems Simulation Methods for the Economic Evaluation of Non-Medicines and Nonsurgical Interventions: A Systematic Literature Review of Quality and Methods for Reproducing Complexity in Health and Health Behaviors
Sep 9, 2025, 16:22 PM -
Real-World Effectiveness, Safety Economic Impact, and Humanistic Outcomes of Bispecific Antibodies (BsAbs) in Third-or-Later-Line (3L+) Treatment of Relapsed/Refractory (R/R) Large B-cell Lymphoma (LBCL): A Systematic Review and Meta-Analysis
Sep 9, 2025, 16:22 PM -
Integrating Patient Perspectives Into Drug Reimbursement Decisions: Insights From Taiwan’s Deliberative HTA Process
Sep 9, 2025, 16:22 PM -
Optimizing Market Access in Europe: A Comparative Analysis of Submission Templates from the EU JCA and National HTA Bodies (HAS, G-BA, ZIN, DMC)
Sep 9, 2025, 16:22 PM -
Detection of a Potential Pericarditis Safety Signal Associated With Azithromycin: Evidence From FAERS Disproportionality Analysis
Sep 9, 2025, 16:22 PM -
Deep Brain Stimulation: A Cost-Saving Treatment Option for Extreme Treatment-Refractory Obsessive-Compulsive Disorder in the UK?
Sep 9, 2025, 16:22 PM -
Gaps in Evidence on Burden and HRQoL in Small-Cell Lung Cancer: Findings From a Targeted Literature Review
Sep 9, 2025, 16:22 PM -
Direct Healthcare Costs (HCCs) Inequalities Associated With Myasthenia Gravis (MG) in Hungary: Claims Database Analysis
Sep 9, 2025, 16:22 PM -
Assessing the Real-World Impact of Earlier Initiation of Anti-Tumor Necrosis Factor vs. Conventional Synthetic DMARDs on Clinical and Patient-Reported Outcomes in Patients With Rheumatoid Arthritis in Europe
Sep 9, 2025, 16:22 PM -
Turning SAP Feedback into HTA-Ready Action: A Semi-Automated Approach for RWD Studies
Sep 9, 2025, 16:22 PM -
Current Methodological Practices to Define Within-Patient Meaningful Change in Rare Diseases: A Targeted Literature Review
Sep 9, 2025, 16:22 PM
